Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors Abstract #1199

Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Aim(s): We aim to characterize the tumor microenvironment (TME) of NEN/NECs on the cellular level in order to define relevant immunophenotypes.
Materials and methods: TMAs of 70 poorly differentiated neuroendocrine carcinomas (PDECs) of all localizations and 20 well differentiated ilial neuroendocrine carcinomas (WDNET) of two different institutions (Charite - Universitätsmedizin Berlin and Zentralklinik Bad Berka) were stained for CD3 expression; 50 PDECs and 20 WDNETs were stained for PD-L1 expression.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1290 PD-L1 Expression is Associated with Grade of Neuroendocrine Tumors
Introduction: Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs).The correlation between Gastroenteropancreatic Neuroendocrine Neoplasms (GEPNENs) and immunocheck point molecule-PD-L1 is still unclear now.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Professor Zhongwu Li
Authors: Li Z, Leng J, Wang H, Li S, ...
#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anamika Gulati
Authors: Yao J C, Fazio N, Li D, Pavel M, ...
Keywords: PDR001, immunotherapy, NET
#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas
Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
Authors: Bollard J, Couderc C, Blanc M, Poncet G, ...
#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).
Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Angela Lamarca
Keywords: immunotherapy